Aggarwal, R., Eggener, S., Heller, G., Xiao, H., Hillman, D., Picus, J., … Morris, M. (2023). UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19). In JOURNAL OF UROLOGY (Vol. 209, pp. E1191–E1191).

Aggarwal, Rahul, Scott Eggener, Glenn Heller, Habn Xiao, David Hillman, Joel Picus, Jennifer Wang, et al. “UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19).” In JOURNAL OF UROLOGY, 209:E1191–E1191, 2023.

Aggarwal R, Eggener S, Heller G, Xiao H, Hillman D, Picus J, et al. UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19). In: JOURNAL OF UROLOGY. 2023. p. E1191–E1191.

Aggarwal, Rahul, et al. “UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19).” JOURNAL OF UROLOGY, vol. 209, 2023, pp. E1191–E1191.

Aggarwal R, Eggener S, Heller G, Xiao H, Hillman D, Picus J, Wang J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Halabi S, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Ryan C, Morris M. UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19). JOURNAL OF UROLOGY. 2023. p. E1191–E1191.